French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes
-
Published:2023-04-30
Issue:1
Volume:18
Page:
-
ISSN:1750-1172
-
Container-title:Orphanet Journal of Rare Diseases
-
language:en
-
Short-container-title:Orphanet J Rare Dis
Author:
Groh MatthieuORCID, Rohmer Julien, Etienne Nicolas, Abou Chahla Wadih, Baudet Antoine, Chan Hew Wai Aurélie, Chenivesse Cécile, Clisson Rusek Irena, Cottin Vincent, Decamp Matthieu, De Groote Pascal, Delahousse Fanny, Duployez Nicolas, Faguer Stanislas, Gottrand Frédéric, Huang Florent, Leblanc Thierry, Magnan Antoine, Martin Thierry, Mortuaire Geoffrey, Néel Antoine, Paris Luc, Petit Arnaud, Rossignol Julien, Schleinitz Nicolas, Soret-Dulphy Juliette, Staumont-Salle Delphine, Terrier Benjamin, Terriou Louis, Viallard Jean-François, Lefèvre Guillaume, Kahn Jean-Emmanuel
Abstract
AbstractEosinophilic-related clinical manifestations are protean and the underlying conditions underpinning eosinophilia are highly diverse. The etiological workup of unexplained eosinophilia/hypereosinophilia can be challenging, and can lead sometimes to extensive, inappropriate, costly and/or invasive investigations. To date, guidelines for the etiological workup and management of eosinophilia are mainly issued by hematologists, and thus mostly cover the scope of clonal hypereosinophilic syndromes (HES). Here, thanks to an extensive literature review, and thanks to the joint work of a large panel of experts involving physicians from both adult and pediatric medicine and from various subspecialties (as well as a representative of a patients’ association representative), we provide recommendations for both the step-by step diagnostic workup of eosinophilia (whether unexplained or within specific contexts) as well as the management and follow-up of the full spectrum of eosinophilic disorders (including clonal, reactive, lymphocytic and idiopathic HES, as well as single-organ diseases). Didactic prescription summaries intended to facilitate the prescription of eosinophil-targeted drugs are also provided, as are practical diagnostic and therapeutic algorithms. Lastly, this set of recommendations also includes a summary intended for general practitioners, as well as an overview of the therapeutic patient education program set up by the French reference center for HES. Further updates will be mandatory as new validated information emerges.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference118 articles.
1. Valent P, Klion AD, Horny H-P, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612.e9. 2. Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47–59. 3. Kahn JE, Groh M, Lefèvre G. (A critical appraisal of) classification of hypereosinophilic disorders. Front Med. 2017;4:216. 4. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–14. 5. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|